The Population Pharmacokinetics of Montelukast in Infants and Children
NCT ID: NCT03238560
Last Updated: 2017-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2016-10-01
2018-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Montelukast With Status Asthmaticus, Ages 6-18
NCT00494572
Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)
NCT00446056
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
NCT00536705
Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.
NCT01581710
Montelukast With Status Asthmaticus, Ages 2-5
NCT00491790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montelukast Chewable Tablet
Montelukast treatment was used at a dosage of 5mg/day once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Month
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Zhao
Head of department of clinical pharmacy and pharmacology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Zhao, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong Provincial Qianfoshan Hospital
Ji'nan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016Montelukast001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.